Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.

ABSTRACT:

Background

The World Health Organization recommends standardised treatment durations for patients with tuberculosis (TB). We identified and validated a host-RNA signature as a biomarker for individualised therapy durations for patients with drug-susceptible (DS)- and multidrug-resistant (MDR)-TB.

Methods

Adult patients with pulmonary TB were prospectively enrolled into five independent cohorts in Germany and Romania. Clinical and microbiological data and whole blood for RNA transcriptomic analysis were collected at pre-defined time points throughout therapy. Treatment outcomes were ascertained by TBnet criteria (6-month culture status/1-year follow-up). A whole-blood RNA therapy-end model was developed in a multistep process involving a machine-learning algorithm to identify

SUBMITTER: Heyckendorf J 

PROVIDER: S-EPMC11967237 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature